We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+97.38%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$766M
AUM Growth
+$277M
Cap. Flow
-$10.8M
Cap. Flow %
-1.41%
Top 10 Hldgs %
89.44%
Holding
31
New
2
Increased
2
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$12.7M
2
AQST icon
Aquestive Therapeutics
AQST
+$10.8M
3
ABVX
Abivax
ABVX
+$4.62M
4
VTVT icon
vTv Therapeutics
VTVT
+$2.94M

Top Sells

Rank Stock Value
1
CRGX
CARGO Therapeutics
CRGX
+$18.2M
2
UPB
Upstream Bio Inc
UPB
+$7.47M
3
PVLA
Palvella Therapeutics
PVLA
+$5.8M
4
AURA icon
Aura Biosciences
AURA
+$2.71M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$1.87M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB.WS
26
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$26.9K ﹤0.01%
133,333
– –
SRZNW icon
27
Surrozen Inc Warrant
SRZNW
$8.86K
$1.78K ﹤0.01%
99,999
– –
CRGX
28
DELISTED
CARGO Therapeutics
CRGX
– –
-4,415,689
Closed -$18.2M
HLVX
29
DELISTED
HilleVax
HLVX
– –
-399,637
Closed -$795K
TNGX icon
30
Tango Therapeutics
TNGX
$4.41B
– –
-210,000
Closed -$1.08M
ARTV
31
Artiva Biotherapeutics
ARTV
$551M
– –
-291,666
Closed -$440K
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q3 2025 Portfolio in Review

As of Q3 2025, Samsara BioCapital held 31 positions worth $766M, up 57% from $489M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Samsara BioCapital's Q3 2025 filing shows 2 new, 2 increased, 9 reduced and 4 closed positions. Its largest new stake was Aquestive Therapeutics: 2,500,000 shares worth $14M. The largest sale was CARGO Therapeutics, an estimated $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Samsara BioCapital's largest Q3 2025 buy was Aquestive Therapeutics: 2,500,000 shares worth $14M.
  • Samsara BioCapital added most to Mineralys Therapeutics in Q3 2025, an estimated $12.7M increase.
  • Samsara BioCapital's biggest Q3 2025 reduction was Upstream Bio Inc, cutting an estimated $7.47M.
  • Samsara BioCapital fully exited CARGO Therapeutics in Q3 2025, selling an estimated $18.2M.
  • Samsara BioCapital's ten largest holdings make up 89% of its $766M portfolio in Q3 2025.
  • Samsara BioCapital opened 2 new positions and closed 4 in Q3 2025.
  • Samsara BioCapital's portfolio value rose 57% quarter-over-quarter to $766M.

Based on Samsara BioCapital's 13F filing for Q3 2025, filed 14 Nov 2025.